Splenic stromal sarcomas in dogs: Outcome and clinicopathological prognostic factors in 32 cases.
canine
chemotherapy
sarcoma
spleen
visceral
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
02 Nov 2023
02 Nov 2023
Historique:
revised:
06
10
2023
received:
13
03
2023
accepted:
19
10
2023
medline:
3
11
2023
pubmed:
3
11
2023
entrez:
2
11
2023
Statut:
aheadofprint
Résumé
Due to the low frequency and the changes in diagnostic techniques and terminology during the last few years, only little clinical information is available on splenic stromal sarcoma (SSS). This multi-institutional study aimed at gathering clinical cases of SSS in dogs and investigates their clinical behaviour, as well as analyse possible clinicopathological prognostic factors, including the use of adjuvant therapy. Dogs with a histologically confirmed SSS that underwent splenectomy were retrospectively included. To be included in the study, either FFPE tissue blocks or multiple tissue sections had to be available for histopathologic and immunohistochemical revision. Clinical and pathological variables, along with adjuvant therapy data, were collected. Cumulative incidence of metastatic disease was analysed through univariate and bivariate analyses. The impact of adjuvant chemotherapy on metastasis incidence and survival was assessed, considering an estimated propensity score. A total of 32 dogs were included. Among them, 22 developed metastases with an incidence of 37.5%, 59.38%, and 65.94% at 6, 12, and 24 months, respectively. Univariate analysis identified mitotic count, total scoring, and necrosis as prognostic factors. In bivariate analysis, mitotic count remained prognostic. The administration of adjuvant chemotherapy did not have an impact on metastasis incidence or survival time. The study found that dogs with SSSs are at high risk of metastasis, although a small subgroup may experience longer survival after splenectomy. Mitotic count was the only variable having a reliable prognostic impact. Adjuvant chemotherapy did not appear to decrease the incidence of metastasis or prolong survival in these dogs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Universita degli Studi di Milano within the CRUI-CARE Agreement
Informations de copyright
© 2023 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.
Références
Spangler WL, Culbertston MR. Prevalence, type, and importance of splenic diseases in dogs: 1480 cases (1985-1989). J Am Vet Med Assoc. 1992;200:829-834.
Eberle N, Von Babo V, Nolte I, Baumgärtner W, Betz D. Splenic masses in dogs. Part 1: epidemiologic, clinical characteristics as well as histopathologic diagnosis in 249 cases (2000-2011). Tierarztl Prax Ausg K Kleintiere Heimtiere. 2012;40:250-260.
Wendelburg KM, Price LL, Burgess KE, Lyons JA, Lew FH, Berg J. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). J Am Vet Med Assoc. 2015;247:393-403.
Leyva FJ, Loughin CA, Dewey CW, Marino DJ, Akerman M, Lesser ML. Histopathologic characteristics of biopsies from dogs undergoing surgery with concurrent gross splenic and hepatic masses: 125 cases (2012-2016). BMC Res Notes. 2018;11:122.
Frey AJ, Betts CW. A retrospective survey of splenectomy in the dog. J Am Anim Hosp Assoc. 1977;13:730-734.
Westein MJ, Carpenter L, Mehlhaffschunk CJ. Nonangiogenic and nonlymphomatous sarcomas of the canine spleen:57 cases (1975-1987). J Am Vet Med Assoc. 1989;195:784-788.
Spangler WL, Culbertston MR, Kass PH. Primary mesenchymal (nonangiomatous /nonlymphomatous) neoplasms occourring in the canine spleen: anatomic classification, immunohistochemistry, and mitotic activity correlated with patient survival. Vet Pathol. 1994;31:37-47.
Day MJ, Lucke VM, Pearson H. A review of patological diagnoses made from 87 canine splenic biopsies. J Small Anim Pract. 1995;36:426-433.
Spangler WL, Kass PH. Pathologic factors affecting postsplenectomy survival in dogs. J Vet Intern Med. 1997;11:166-171.
Spangler WL, Kass PH. Pathologic and prognostic characteristics of splenomegaly in dogs due to fibrohistiocytic nodules: 98 cases. Vet Pathol. 1998;35:488-498.
Moore AS, Frimbergher AE, Sullivan N, Moore PF. Histologic and himmunoistochemical review of splenic fibrohistocytic nodules in dogs. J Vet Intern Med. 2012;26:1164-1168.
Linden D, Liptak JM, Vinayak A, Grimes JA, Sandey M, Smiley W. Outcomes and prognostic variables associated with primary abdominal visceral soft tissue sarcomas in dogs: a veterinary Society of Surgical Oncology retrospective study. Vet Comp Oncol. 2019;17:265-270.
Wittenberns BM, Thamm DH, Palmer EP, Regan DP. Canine non-Angiogenic, non-myogenic splenic stromal sarcoma: a retrospective Clinicopathological analysis and investigation of Podoplanin as a marker of tumour Histogenesis. J Comp Pathol. 2021;188:1-12.
Spröhnle-Barrera CH, McGhie J, Allavena RE, Owen HC, Palmieri C, Barnes TS. Epidemiology and survival of dogs diagnosed with splenic lymphoid hyperplasia, complex hyperplasia, Stromal Sarcoma and Histiocytic Sarcoma. Animals. 2022;12:960.
Valli VE, Bienzle D, Meuten DJ, Linder KR. Tumors of the hemolymphatic system. In: Meuten DJ, ed. Tumors in Domestic Animals. Vol 2016. John Wiley&Sons, Ames; 2016:203-321.
Meuten DJ, Moore FM, George JW. Mitotic count and the field of view area: time to standardize. Vet Pathol. 2016;53:7-9.
Gower KLA, Liptak J, Culp VTN, Bravo L, Powers B, Withrow SJ. Splenic liposarcomas in dogs:13 cases (2002-2012). J Am Vet Med Assoc. 2015;247:1404-1407.
Kuntz CA, Dernell WS, Powers BE, Devitt C, Straw RC, Withrow SJ. Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986-1996). J Am Vet Med Assoc. 1997;211:1147-1151.
Dennis MM, McSporran KD, Bacon NJ, Schulman FY, Foster RA, Powers BE. Prognostic factors for cutaneous and subcutaneous soft tissue sarcomas in dogs. Vet Pathol. 2011;48:73-84.
Avallone G, Rasotto R, Chambers JK, Miller AD, Behling-Kelly E, Monti P. Review of histological grading Systems in Veterinary Medicine. Vet Pathol. 2021;58:809-828.
Avallone G, Helmbold P, Caniatti M, Stefanello D, Nayak RC, Roccabianca P. The spectrum of canine cutaneous perivascular wall tumors: morphologic, phenotypic and clinical characterization. Vet Pathol. 2007;44:607-620.
Sabattini S, Rigillo A, Foiani G, Marconato L, Vascellari M, Greco A. Clinicopathologic features and biologic behavior of canine splenic nodules with stromal, histiocytic and lymphoid components. Front Vet Sci. 2022;9:962685.
Sabattini S, Lopparelli RM, Rigillo A, Giantin M, Renzi A, Matteo C. Canine splenic nodular lymphoid lesions: immunophenotyping, proliferative activity, and clonality assessment. Vet Pathol. 2018;55:645-653.
Roccabianca P, Schulman FY, Avallone G, et al. Growth patterns of soft tissue tumors. In: Kiupel M, ed. Surgical Pathology of Tumors of Domestic Animals Volume3: Tumors of Soft Tissue. Davis-Yhompson Foundation; 2020:32-49.
Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9:191-192.
Boracchi P, Roccabianca P, Avallone G, Marano G. Kaplan-Meier curves, cox model, and P-values are not enough for the prognostic evaluation of tumor markers: statistical suggestions for a more comprehensive approach. Vet Pathol. 2021;58:795-808.
Austin PC, Allignol A, Fine JP. The number of primary events per variable affects estimation of the subdistribution hazard competing risks model. J Clin Epidemiol. 2017;83:75-84.
Heinze G, Jüni P. An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J. 2011;32(14):1704-1708.
Richards CH, Mohammed Z, Qayyum T, Horgan PG, McMillan DC. The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. Future Oncol. 2011;7:1223-1235.
Moore FM, Williams B, Bertram CA, et al. Tumor Necrosis Guideline, version 1.2. Veterinary Cancer Guidelines and Protocols; 2021 http://vetcancerprotocols.org
Sorenmo KU, Jeglum KA, Helfand SC. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. J Vet Intern Med. 1993;7:370-376.
Wendelburg KM, O'tolle TE, McCobb E, Price LL, Lyons JA, Berg J. Risk factors for perioperative death in dogs undergoing splenectomy for splenic masses: 539 cases (2001-2012). J Am Vet Med Assoc. 2014;245:1382-1390.
Finotello R, Henriques J, Sabattini S, et al. A retrospective analysis of chemotherapy swich suggests improved outcome in surgically removed, biologically aggressive canine Haemangiosarcoma. Vet Comp Oncologia. 2016;10:493-503.
Matsuyama A, Poirier VJ, Mantovani F, Foster RA, Mutsaers AJ. Adjuvant doxorubicin with or without metronomic cyclophosphamide for canine splenic Hemangiosarcoma. J Am Anim Hosp Assoc. 2017;53:304-312.
Ebrahim Valojerdi A, Janani L. A brief guide to propensity score analysis. Med J Islam Repub Iran. 2018;32:122.